Progressing vision to expand the reach of targeted radiopharmaceuticals to large patient populations Anticipating multiple milestones in the next 12 months, including initiation of Phase 1b clinical trial...
BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large...
U.S. FDA Fast Track designation granted to AKY-1189 1 for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have progressed on or after prior systemic therapies...
The Brazilian fintech company is purportedly set to trade from Jan. 29.
Economic data helped stocks move higher as it showed that the Fed's decision on interest rates may not interrupt the bullish case for equities in 2026.
Aktis Oncology, which recently had its IPO, has gained substantial backing from Big Pharma mainstay Eli Lilly. Investors should take note of the biotech firm.
BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (“Aktis”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large...
Akoustis Technologies files for Chapter 11 to facilitate a strategic sale while addressing legal issues with Qorvo.Quiver AI SummaryAkoustis Technologies, Inc. has announced that it has voluntarily filed...
For Immediate ReleaseChicago, IL – December 10, 2024 – Today, Zacks Equity Research discusses RF Industries RFIL and Akoustis Technologies AKTS.Industry: Radio-Frequency SemiconductorsLink: https://www.zacks.com/commentary/2380991/2-radio-frequency-stocks-to-watch-in-a-challenging-industryThe...